NYSE:NUVB Nuvation Bio (NUVB) Stock Price, News & Analysis $2.80 +0.10 (+3.70%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Nuvation Bio Stock (NYSE:NUVB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nuvation Bio alerts:Sign Up Key Stats Today's Range$2.66▼$2.8150-Day Range$2.00▼$3.0752-Week Range$1.22▼$4.16Volume3.43 million shsAverage Volume2.41 million shsMarket Capitalization$944.08 millionP/E RatioN/ADividend YieldN/APrice Target$6.60Consensus RatingBuy Company OverviewNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Read More… ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Nuvation Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreNUVB MarketRank™: Nuvation Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 608th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvation Bio has only been the subject of 3 research reports in the past 90 days.Read more about Nuvation Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nuvation Bio are expected to decrease in the coming year, from ($0.40) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nuvation Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.94% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Nuvation Bio has recently increased by 13.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.94% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Nuvation Bio has recently increased by 13.54%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentNuvation Bio has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nuvation Bio this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for NUVB on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows7 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $220,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.07% of the stock of Nuvation Bio is held by insiders.Percentage Held by Institutions61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvation Bio's insider trading history. Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVB Stock News HeadlinesNuvation Bio’s Q3 2024 Highlights and Future ProspectsNovember 21 at 5:33 AM | markets.businessinsider.comNuvation Bio to Present at the Jefferies London Healthcare ConferenceNovember 12, 2024 | finance.yahoo.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 23, 2024 | DTI (Ad)Nuvation Bio (NYSE:NUVB) Stock, Option ChainNovember 12, 2024 | benzinga.comNuvation Bio’s Global Challenges: Navigating Risks in China Amid Geopolitical TensionsNovember 8, 2024 | markets.businessinsider.comNuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6, 2024 | businesswire.comNuvation Bio Inc. (NUVB): Promising Penny Stock with Strong Oncology PipelineNovember 6, 2024 | msn.comNuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish MarketOctober 21, 2024 | seekingalpha.comSee More Headlines NUVB Stock Analysis - Frequently Asked Questions How have NUVB shares performed this year? Nuvation Bio's stock was trading at $1.51 at the beginning of the year. Since then, NUVB stock has increased by 85.8% and is now trading at $2.8050. View the best growth stocks for 2024 here. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) released its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.02. The business had revenue of $0.73 million for the quarter. Who are Nuvation Bio's major shareholders? Nuvation Bio's top institutional investors include FMR LLC (11.73%), State Street Corp (1.67%), Geode Capital Management LLC (1.62%) and Charles Schwab Investment Management Inc. (0.56%). Insiders that own company stock include Fund V LP Omega, Oleg Nodelman, Xiangmin Cui and Robert Mashal. View institutional ownership trends. How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nuvation Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvation Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings11/06/2024Today11/22/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NUVB CUSIPN/A CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.60 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+135.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,800,000.00 Net MarginsN/A Pretax Margin-24,619.84% Return on Equity-21.89% Return on Assets-17.86% Debt Debt-to-Equity RatioN/A Current Ratio9.57 Quick Ratio9.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book1.88Miscellaneous Outstanding Shares336,570,000Free Float319,503,000Market Cap$944.08 million OptionableOptionable Beta1.35 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NYSE:NUVB) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.